<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03569098</url>
  </required_header>
  <id_info>
    <org_study_id>D-FR-52120-237</org_study_id>
    <nct_id>NCT03569098</nct_id>
  </id_info>
  <brief_title>Dysport in Hallux Abducto Valgus (HAV) Phase IIa</brief_title>
  <acronym>DYSTANCE</acronym>
  <official_title>A Multiple-dose, Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dysport for the Treatment of Pain Associated With Hallux Abducto Valgus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of treatment with
      multiple doses of Dysport in adults suffering from clinically significant pain associated
      with HAV who have not undergone surgery for their condition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2018</start_date>
  <completion_date type="Actual">May 22, 2020</completion_date>
  <primary_completion_date type="Actual">December 17, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the daily Numeric Pain Rating Scale (NPRS) score</measure>
    <time_frame>Change from baseline to Week 8 (double blind period)</time_frame>
    <description>The daily NPRS score averaged over the 7 consecutive days prior to baseline and Week 8. The NPRS is based on an 11-point scale ranging from 0 to 10, where 0 equals &quot;no pain&quot; and 10 equals &quot;worst possible pain&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the daily NPRS score averaged over the 7 consecutive days prior to each scheduled assessment timepoint (except Week 8 DB)</measure>
    <time_frame>Change from baseline to Week 4 and 12 (double blind period) and Day 1, Week 4, 8 and 12 (open label period)</time_frame>
    <description>The NPRS is based on an 11-point scale ranging from 0 to 10, where 0 equals &quot;no pain&quot; and 10 equals &quot;worst possible pain&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the daily modified Foot Function Index (mFFI) disability subscale score averaged over the 7 consecutive days prior to each scheduled assessment timepoint</measure>
    <time_frame>Change from baseline to Week 4, 8 and 12 (double blind period) and Day 1, Week 4, 8 and 12 (open label period)</time_frame>
    <description>mFFI items are rated using numeric rating scales ranging from 0 to 10 and cover a period of the 'past' 24 hours. The poles are labelled &quot;no pain&quot; and &quot;worst pain imaginable&quot; (pain), &quot;no difficulty&quot; and &quot;so difficult unable&quot; (disability), and &quot;none of the time&quot; and &quot;all of the time&quot; (limitations). For each item, the subject is asked to record the number value which best corresponds to the effect of the foot complaints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the daily mFFI pain subscale score averaged over the 7 consecutive days prior to each scheduled assessment timepoint</measure>
    <time_frame>Change from baseline to Week 4, 8 and 12 (double blind period) and Day 1, Week 4, 8 and 12 (open label period)</time_frame>
    <description>mFFI items are rated using numeric rating scales ranging from 0 to 10 and cover a period of the 'past' 24 hours. The poles are labelled &quot;no pain&quot; and &quot;worst pain imaginable&quot; (pain), &quot;no difficulty&quot; and &quot;so difficult unable&quot; (disability), and &quot;none of the time&quot; and &quot;all of the time&quot; (limitations). For each item, the subject is asked to record the number value which best corresponds to the effect of the foot complaints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the daily mFFI total score averaged over the 7 consecutive days prior to each scheduled assessment timepoint.</measure>
    <time_frame>Change from baseline to Week 4, 8 and 12 (double blind period) and Day 1, Week 4, 8 and 12 (open label period)</time_frame>
    <description>mFFI items are rated using numeric rating scales ranging from 0 to 10 and cover a period of the 'past' 24 hours. The poles are labelled &quot;no pain&quot; and &quot;worst pain imaginable&quot; (pain), &quot;no difficulty&quot; and &quot;so difficult unable&quot; (disability), and &quot;none of the time&quot; and &quot;all of the time&quot; (limitations). For each item, the subject is asked to record the number value which best corresponds to the effect of the foot complaints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the daily mFFI activity limitation subscale score averaged over the 7 consecutive days prior to each scheduled assessment timepoint</measure>
    <time_frame>Change from baseline to Week 4, 8 and 12 (double blind period) and Day 1, Week 4, 8 and 12 (open label period)</time_frame>
    <description>mFFI items are rated using numeric rating scales ranging from 0 to 10 and cover a period of the 'past' 24 hours. The poles are labelled &quot;no pain&quot; and &quot;worst pain imaginable&quot; (pain), &quot;no difficulty&quot; and &quot;so difficult unable&quot; (disability), and &quot;none of the time&quot; and &quot;all of the time&quot; (limitations). For each item, the subject is asked to record the number value which best corresponds to the effect of the foot complaints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hallux angular measurements (HV) angle as measured directly by weight-bearing anterior-posterior radiographs at each scheduled assessment timepoint</measure>
    <time_frame>Change from baseline to Week 4, 8 and 12 (double blind period) and Day 1, Week 4, 8 and 12 (open label period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in intermetatarsal angle as measured directly by weight-bearing anterior-posterior radiographs at each scheduled assessment timepoint</measure>
    <time_frame>Change from baseline to Week 4, 8 and 12 (double blind period) and Day 1, Week 4 and 12 (open label period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to retreatment</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient Global Impression of Severity (PGI-S) of foot pain score at each scheduled assessment timepoint</measure>
    <time_frame>Change from baseline to Week 4, 8 and 12 (double blind period) and Day 1, Week 4, 8 and 12 (open label period)</time_frame>
    <description>Assessment of PGI-S of foot pain will be conducted by the subject using a 4-point Likert scale (from 0: no pain to 3: severe pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PGI-S disability score at each scheduled assessment timepoint</measure>
    <time_frame>Change from baseline to Week 4, 8 and 12 (double blind period) and Day 1 and Week 8 (open label period)</time_frame>
    <description>Assessment of PGI-S of foot pain will be conducted by the subject using a 4-point Likert scale (from 0: no pain to 3: severe pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I) of foot pain score at the scheduled assessment timepoint</measure>
    <time_frame>Change from baseline to Week 4, 8 and 12 (double blind period) and Day 1 and Week 8 (open label period)</time_frame>
    <description>Assessment of PGI-I of foot pain will be conducted by the subject using a 7-point Likert scale (from -3: very much worse to +3: very much improved).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGI-I disability score at the scheduled assessment timepoint</measure>
    <time_frame>Change from baseline to Week 4, 8 and 12 (double blind period) and Day 1 and Week 8 (open label period)</time_frame>
    <description>Assessment of PGI-I of foot pain will be conducted by the subject using a 7-point Likert scale (from -3: very much worse to +3: very much improved).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in functional outcome as measured by the 36 item short form survey (SF-36) at each scheduled assessment timepoint</measure>
    <time_frame>Baseline, Week 8 and 12 (double blind period) and Day 1, Week 8 and 12 (open label period)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>Hallux Abductovalgus</condition>
  <arm_group>
    <arm_group_label>Dysport Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dysport Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection of Placebo on day 1 of cycle 1 (double-blind period)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Botulinum toxin type A</intervention_name>
    <description>Investigators will inject the reconstituted solution into foot muscles.</description>
    <arm_group_label>Dysport Dose 1</arm_group_label>
    <arm_group_label>Dysport Dose 2</arm_group_label>
    <other_name>AbobotulinumtoxinA (DysportÂ®)</other_name>
    <other_name>Clostridium botulinum toxin type A haemagglutinin complex (BTX-A-HAC)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Investigators will inject the reconstituted solution into foot muscles.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of HAV

          -  Painful HAV in the study foot at Baseline

        Exclusion Criteria:

          -  Flat or square metatarsal head, metatarsus primus elevates, or severe cavus/planus in
             the study foot

          -  Other podiatric or orthopedic condition which would interfere with the evaluation of
             pain and/or function

          -  Medical history or clinical evidence of any vascular disease and/or diabetic condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NEA Baptist Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Applied Research Center of Arkansas, Inc</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research Inc.</name>
      <address>
        <city>Castro Valley</city>
        <state>California</state>
        <zip>94546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limb Preservation Platform, Inc.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwestern Academic Limb Salvage Alliance</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foot and Ankle Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Foot and Ankle Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Spine and Orthopedics</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LCC Medical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Conquest Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Research Network</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Podiatry 1st</name>
      <address>
        <city>Belleville</city>
        <state>Illinois</state>
        <zip>62226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weil Foot &amp; Ankle Institute</name>
      <address>
        <city>Des Plaines</city>
        <state>Illinois</state>
        <zip>60016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosalind Franklin Clinic</name>
      <address>
        <city>North Chicago</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foot and Ankle Center of Illinois</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chesapeake Research Group</name>
      <address>
        <city>Pasadena</city>
        <state>Maryland</state>
        <zip>21122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Allen M. Jacobs and Associates</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankle and Foot Care Centers</name>
      <address>
        <city>Youngstown</city>
        <state>Ohio</state>
        <zip>22801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research International</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foot and Ankle Center</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrisburg Foot and Ankle Center, INC</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Futuro Clinical Trials, LLC</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bio X Cell Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Gulf Coast Medical Group</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Foot &amp; Ankle</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrisonburg Foot and Ankle Clinic</name>
      <address>
        <city>Harrisonburg</city>
        <state>Virginia</state>
        <zip>22801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1Foot 2Foot Centre for Foot and Ankle Care, PC</name>
      <address>
        <city>Suffolk</city>
        <state>Virginia</state>
        <zip>23434</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martinsville Research Institute, Inc.</name>
      <address>
        <city>Salem</city>
        <state>West Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <disposition_first_submitted>February 28, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>February 28, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 3, 2020</disposition_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hallux Valgus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Hemagglutinins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

